Cargando…

Tissue-Based Approaches to Study Pharmacodynamic Endpoints in Early Phase Oncology Clinical Trials

Anti-cancer clinical drug development is currently costly and slow with a high attrition rate. There is thus an urgent and unmet need to integrate pharmacodynamic biomarkers into early phase clinical trials in the framework provided by the “pharmacologic audit trail” in order to overcome this challe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ang, Joo Ern, Kaye, Stan, Banerji, Udai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bentham Science Publishers 2012
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3531821/ https://www.ncbi.nlm.nih.gov/pubmed/22974395 http://dx.doi.org/10.2174/138945012803530062

Ejemplares similares

A study of 1088 consecutive cases of electrolyte abnormalities in oncology phase I trials
por: Ingles Garces, Alvaro H., et al.
Publicado: (2018)

The Importance of Endpoints in Oncology Clinical Trials
por: Faiman, Beth
Publicado: (2023)

Endpoint surrogacy in oncology Phase 3 randomised controlled trials
por: Zhang, Jianrong, et al.
Publicado: (2020)

A study of motivations and expectations of patients seen in phase 1 oncology clinics
por: Dolly, Saoirse O., et al.
Publicado: (2016)

A risk-based approach to experimental early phase clinical trials during the COVID-19 pandemic
por: Tiu, Crescens, et al.
Publicado: (2020)

Bayesian dose regimen assessment in early phase oncology incorporating pharmacokinetics and pharmacodynamics
por: Gerard, Emma, et al.
Publicado: (2021)

Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology
por: Sherrill, Beth, et al.
Publicado: (2012)

Health-related quality of life as an endpoint in oncology phase I trials: a systematic review
por: Fiteni, Frédéric, et al.
Publicado: (2019)

Study protocol for a randomised controlled trial of enhanced informed consent compared to standard informed consent to improve patient understanding of early phase oncology clinical trials (CONSENT)
por: Pal, Abhijit, et al.
Publicado: (2021)

Clinical Trials with Biologic Primary Endpoints in Immuno-oncology: Concepts and Usage
por: Isaacs, James, et al.
Publicado: (2022)

Useful pharmacodynamic endpoints in children: selection, measurement, and next steps
por: Kelly, Lauren E, et al.
Publicado: (2018)

A stratified adaptive two-stage design with co-primary endpoints for phase II clinical oncology trials
por: Cabarrou, Bastien, et al.
Publicado: (2022)

Discrepancies in endpoints between clinical trial protocols and clinical trial registration in randomized trials in oncology
por: Serpas, Victoria J., et al.
Publicado: (2018)

Perceptions and Referral Trends into Phase I Oncology Trials: Results of a Clinical Survey
por: Brunetto, Andre, et al.
Publicado: (2011)

Challenges in translating endpoints from trials to observational cohort studies in oncology
por: Ording, Anne Gulbech, et al.
Publicado: (2016)

Improving phase ii oncology trial using best observed RECIST response as an endpoint by modelling continuous tumour measurements
por: Lin, Chien-Ju, et al.
Publicado: (2015)

Improving phase II oncology trials using best observed RECIST response as an endpoint by modelling continuous tumour measurements
por: Lin, Chien‐Ju, et al.
Publicado: (2017)

Comparing the Efficacy of Drug Regimens for Pulmonary Tuberculosis: Meta-analysis of Endpoints in Early-Phase Clinical Trials
por: Bonnett, Laura J, et al.
Publicado: (2017)

Complexity of design in early phase respiratory clinical trials; evaluating impact of primary endpoints and sponsor size
por: Marco-Ariño, Nicolas, et al.
Publicado: (2021)

Patient relevant endpoints in oncology: current issues in the context of early benefit assessment in Germany
por: Dabisch, Inna, et al.
Publicado: (2014)

Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?
por: Postel-Vinay, S, et al.
Publicado: (2009)

Biomarker changes as surrogate endpoints in early‐phase trials in heart failure with reduced ejection fraction
por: Savarese, Gianluigi, et al.
Publicado: (2022)

Early Benefit Assessments in Oncology in Germany: How Can a Clinically Relevant Endpoint Not Be Relevant to Patients?
por: Ruof, Jörg, et al.
Publicado: (2015)

Analysis of composite endpoints in gene expression studies in oncology
por: Marhoon, ZA, et al.
Publicado: (2015)

Clinical Trial Endpoints and Their Clinical Meaningfulness in Early Stages of Alzheimer’s Disease
por: Cohen, S., et al.
Publicado: (2022)

Pitfall in the Design and Analysis of Comparative Oncology Trials With a Time-to-Event Endpoint and Recommendations
por: McCaw, Zachary R, et al.
Publicado: (2022)

Surrogate Endpoints for Overall Survival in Immune-Oncology Trials of Advanced Gastro-Esophageal Carcinoma
por: Li, Yuan Fang, et al.
Publicado: (2022)

Pharmacodynamic Modelling of Biomarker Data in Oncology
por: Jackson, Robert C.
Publicado: (2012)

Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology
por: Bruin, Maaike A. C., et al.
Publicado: (2022)

Statistical Considerations for Analyses of Time-To-Event Endpoints in Oncology Clinical Trials: Illustrations with CAR-T Immunotherapy Studies
por: Li, Yimei, et al.
Publicado: (2022)

A feasibility study of combined epigenetic and vaccine therapy in advanced colorectal cancer with pharmacodynamic endpoint
por: Bever, Katherine M., et al.
Publicado: (2021)

Precision Oncology for Cancer Immunotherapies in Early-Phase Clinical Trials
por: Paliard, Xavier, et al.
Publicado: (2019)

IPF clinical trial design and endpoints
por: Nathan, Steven D., et al.
Publicado: (2014)

Using short-term endpoints to improve interim decision making and trial duration in two-stage phase II trials with nested binary endpoints
por: Zocholl, Dario, et al.
Publicado: (2023)

Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?
por: Kemp, Robert, et al.
Publicado: (2017)

Research Question, Objectives, and Endpoints in Clinical and Oncological Research: A Comprehensive Review
por: Purna singh, Addanki, et al.
Publicado: (2022)

Are component endpoints equal? A preference study into the practice of composite endpoints in clinical trials
por: Vaanholt, Melissa C.W., et al.
Publicado: (2018)

Design considerations for early-phase clinical trials of immune-oncology agents
por: Wages, Nolan A., et al.
Publicado: (2018)

Early phase clinical trials in oncology: realising the potential of seamless designs
por: Jaki, Thomas, et al.
Publicado: (2023)

Outcome switching in randomized controlled oncology trials reporting on surrogate endpoints: a cross-sectional analysis
por: Falk Delgado, Alberto, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_95uoqftgs92as38gsnq4uuapkd